{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:06:19Z","timestamp":1789686379944,"version":"4.0.1"},"reference-count":41,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013478","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T10:58:36Z","timestamp":1573642716000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmaceutical policies: effects of educational or regulatory policies targeting prescribers"],"prefix":"10.1002","volume":"2019","author":[{"given":"Fatima","family":"Suleman","sequence":"first","affiliation":[{"name":"University of KwaZulu-Natal; Discipline of Pharmaceutical Sciences, School of Health Sciences; Private Bag X54001 Durban KZN South Africa 4000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Movik","sequence":"additional","affiliation":[{"name":"Norwegian Institute of Public Health; Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"issue":"19","key":"10.1002\/14651858.CD013478-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/ajhp\/57.19.1778","article-title":"Impact of interventions designed to increase market share and prescribing of fexofenadine at HMOs","volume":"57","author":"Benedetto","year":"2000","journal-title":"American Journal of Health-system Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"103-23","DOI":"10.2190\/8FR4-QYY1-7MYG-2AGJ","article-title":"A Controlled Study of the Effects of State Surveillance on Indicators of Problematic and Non-Problematic Benzodiazepine Use in a Medicaid Population","volume":"34","author":"Ross-Degnan","year":"2004","journal-title":"The International Journal of Psychiatry in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0149-2918(04)90030-6","article-title":"A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders","volume":"26","author":"Simoni-Wastila","year":"2004","journal-title":"Clinical Therapeutics"},{"issue":"2-3","key":"10.1002\/14651858.CD013478-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.healthpol.2006.07.005","article-title":"Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals","volume":"81","author":"Andersson","year":"2007","journal-title":"Health Policy"},{"issue":"3","key":"10.1002\/14651858.CD013478-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/heapol\/czg038","article-title":"Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience","volume":"18","author":"Chou","year":"2003","journal-title":"Health Policy and Planning"},{"issue":"1","key":"10.1002\/14651858.CD013478-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clinthera.2011.01.012","article-title":"Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study","volume":"33","author":"Lu","year":"2011","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004397.pub2","article-title":"Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews","author":"Aaserud","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0008|cit8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004397.pub2","article-title":"Pharmaceutical policies: effects on rational drug use","author":"Aaserud","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013478-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005979.pub2","article-title":"Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies","author":"Acosta","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013478-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001175.pub4","article-title":"Computer-generated reminders delivered on paper to healthcare professionals: effects on professional practice and healthcare outcomes","author":"Arditi","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013478-BIB0011|cit11","unstructured":"Chalker J Managing Access to Medicines and Health Technologies -- Promoting rational prescribing. Part II, Chapter 29 Available at apps.who.int\/medicinedocs\/documents\/s19577en\/s19577en.pdf"},{"issue":"3","key":"10.1002\/14651858.CD013478-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/annonc\/mdp581","article-title":"Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO\/EAPC Opioid Policy Initiative","volume":"21","author":"Cherny","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013478-BIB0013|cit13","unstructured":"Cochrane Effective Practice Organisation of Care (EPOC) What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors, 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors (accessed 07 October 2019)"},{"key":"10.1002\/14651858.CD013478-BIB0014|cit14","unstructured":"Effective Practice Organisation of Care (EPOC) Suggested risk of bias criteria for EPOC reviews. EPOC Resources for review authors, 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors (accessed 07 October 2019)"},{"key":"10.1002\/14651858.CD013478-BIB0015|cit15","unstructured":"Cochrane Effective Practice Organisation of Care (EPOC) EPOC worksheets for preparing a Summary of Findings (SoF) table using GRADE. EPOC Resources for review authors, 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors (accessed 07 October 2019)"},{"key":"10.1002\/14651858.CD013478-BIB0016|cit16","unstructured":"Cochrane Effective Practice Organisation of Care (EPOC) Reporting the effects of an intervention in EPOC reviews. EPOC Resources for review authors, 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors (accessed 07 October 2019)"},{"issue":"6","key":"10.1002\/14651858.CD013478-BIB0017|cit17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000125.pub5","article-title":"Local opinion leaders: effects on professional practice and healthcare outcomes","author":"Flodgren","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003030.pub2","article-title":"Continuing education meetings and workshops: effects on professional practice and health care outcomes","author":"Forsetlund","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013478-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004398.pub3","article-title":"Printed educational materials: effects on professional practice and healthcare outcomes","author":"Gigu\u00e8re","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD013478-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"The GRADE working group","year":"2004","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013478-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008654","article-title":"Pharmaceutical policies: effects of restrictions on reimbursement","author":"Green","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013478-BIB0022|cit22","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD013478-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000259.pub3","article-title":"Audit and feedback: effects on professional practice and healthcare outcomes","author":"Ivers","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013478-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007017.pub2","article-title":"Pharmaceutical policies: effects of cap and co-payment on rational use of medicines","author":"Luiza","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013478-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.25100\/cm.v44i1.1028","article-title":"Prescribing patterns and economic costs of proton pump inhibitors in Colombia","volume":"44","author":"Machado-Alba","year":"2013","journal-title":"Colombia Medica"},{"issue":"4","key":"10.1002\/14651858.CD013478-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"605-13","DOI":"10.1111\/j.1365-2125.2012.04271.x","article-title":"How could undergraduate education prepare new graduates to be safer prescribers?","volume":"74","author":"McLellan","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD013478-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"e004623","DOI":"10.1136\/bmjopen-2013-004623","article-title":"Behaviour change interventions to promote prescribing of generic drugs: a rapid evidence synthesis and systematic review","volume":"4","author":"Moe-Byrne","year":"2014","journal-title":"BMJ Open"},{"issue":"4","key":"10.1002\/14651858.CD013478-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000409.pub2","article-title":"Educational outreach visits: effects on professional practice and health care outcomes","author":"O\u2019Brien","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013478-BIB0029|cit29","unstructured":"Organization of Economic Co-operation and Development Health at a Glance 2009: OECD Indicators OECD data 2009"},{"key":"10.1002\/14651858.CD013478-BIB0030|cit30","unstructured":"OECD Health at a Glance 2013: OECD Indicators dx.doi.org\/10.1787\/health_glance-2013-en"},{"key":"10.1002\/14651858.CD013478-BIB0031|cit31","unstructured":"OECD OECD Health Data data.oecd.org\/healthres\/pharmaceutical-spending.htm"},{"issue":"10","key":"10.1002\/14651858.CD013478-BIB0032|cit32","first-page":"1423","article-title":"No magic bullets: a systematic review of 102 trials of interventions to improve professional practice","volume":"153","author":"Oxman","year":"1995","journal-title":"Canadian Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD013478-BIB0033|cit33","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011703","article-title":"Pharmaceutical policies: effects of policies regulating drug insurance schemes","author":"Pantoja","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013478-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011830","article-title":"Pharmaceutical policies: effects of sales and dispensing policies","author":"Pe\u00f1aloza","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013478-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006731.pub2","article-title":"Pharmaceutical policies: effects of financial incentives for prescribers","author":"Rashidian","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013478-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2125.2012.04186.x","article-title":"Prescribing and the core curriculum for tomorrow\u2019s doctors: BPS curriculum in clinical pharmacology and prescribing for medical students.","volume":"74","author":"Ross","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2190\/8FR4-QYY1-7MYG-2AGJ","article-title":"A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population","volume":"34","author":"Ross-Degnan","year":"2004","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013478-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/678066","article-title":"Economic Impact of Redundant Antimicrobial Therapy in US Hospitals","volume":"35","author":"Schultz","year":"2014","journal-title":"Infection Control and Hospital Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD013478-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2307\/3350142","article-title":"Improving drug prescribing in primary care: a critical analysis of the experimental literature","volume":"67","author":"Soumerai","year":"1989","journal-title":"Milbank Quarterly"},{"issue":"6","key":"10.1002\/14651858.CD013478-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jpainsymman.2014.02.013","article-title":"Legal barriers in accessing opioid medicines: results of the ATOME quick scan of national legislation of eastern European countries","volume":"48","author":"Vranken","year":"2014","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD013478-BIB0041|cit41","article-title":"Chapter 7: Regulation of pharmaceutical promotion - Why does regulation matter?","volume-title":"Understanding and responding to pharmaceutical promotion: A practical guide","author":"Ziganshina","year":"2010"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013478\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T09:47:34Z","timestamp":1639216054000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013478"}},"subtitle":[],"editor":[{"name":"Cochrane Effective Practice and Organisation of Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013478","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]}}}